The Beauty Standard with Dr. Roy Kim

Letybo: The New Botox Alternative for Facial Rejuvenation

• Dr. Roy Kim

Share episode

Discover how a Korean beauty powerhouse is shaking up the American injectable market with Letybo, the neurotoxin that's challenging Botox's long-standing dominance. Known as Botulax in South Korea where it commands an astonishing 65% market share, this newly FDA-approved treatment is making waves with its strategic US launch through distributor Benev.

What makes Letybo truly disruptive isn't just its albumin-free formulation or quick 1-4 day onset time—it's the economics. At potentially 20-30% less than Botox, treatments become dramatically more affordable. Imagine masseter reduction treatments dropping from $960 to $640, creating a $320 savings that could make aesthetic treatments accessible to entirely new patient demographics. For practitioners, this creates fascinating opportunities to explore innovative Korean beauty trends like "glass skin facials" with microdose neurotoxins or treat secondary areas that previously felt economically impractical.

Yet this price revolution raises profound questions about the future of aesthetic medicine. Will clinics adapt their business models as profit margins potentially shrink from 60% to 45%? Can the industry overcome patient perceptions that higher prices equal better quality? And most intriguingly—if neurotoxins become as routine as facials, does that diminish their medical significance or finally position aesthetics as preventative care? Join me as we explore these questions and discover what Hugel Pharmaceutical's ambitious US strategy means for providers, patients, and our understanding of beauty itself. Share your thoughts with me on Instagram or Twitter @DrRoyKim—I'm eager to hear your perspective on this aesthetic revolution.

Thank you for tuning in to this week's episode of "The Beauty Standard" with Dr. Roy Kim! If you enjoyed this episode, please make sure to subscribe, rate, and leave us a review on your favorite podcast platform. Your support helps us continue to bring you the latest insights in aesthetic medicine and beauty trends.

Connect with us on social media on Instagram - @drroykim - or X - @drroykim- for more exclusive content, behind-the-scenes looks, and expert advice from Dr. Kim. Feel free to submit your questions or suggestions for future episodes – we'd love to hear from you!

Join us next week as we explore another fascinating topic in the world of beauty, and remember: your body, your choice, your standard!

Speaker 1:

Welcome to the Beauty Standard with Dr Roy Kim. This is your real host, dr Roy Kim, with my real voice. Today we're going to be unpacking the hottest development in cosmetic plastic surgery injectables Latibo. So Latibo is a Korean neurotoxin brand name and is poised to disrupt the US aesthetics market. If you've ever wondered why Botox alternatives matter or how cost savings could revolutionize treatment options, this episode is just for you. This episode is just for you, so let's dive in. First, the basics.

Speaker 1:

Latibo, known in Korea as Botulax, is Hugo Pharmaceutical's answer to Botox by Allergan. Latibo has been FDA approved for globellar lines since March of 2024. Now granted, it's March of 2025. They just started selling it a couple days ago. So, interestingly, botulax is the most popular neurotoxin in South Korea. It holds a staggering 65% of market share in Korea. Now, through a strategic partnership with California-based distributor Benev, it's hitting US clinics literally this week.

Speaker 1:

So what makes Latibo stand out For providers? It's nearly identical to existing toxins in storage, reconstitution and longevity. So it lasts about three to four months. Just like Botox For patients, it does act pretty fast, specifically in typically one to four months. Just like Botox For patients, it does act pretty fast, specifically in typically one to four days, which rivals Dysport's quick onset. But the real story it's pricing. In Korea, latibo costs 20 to 30 percent less than Botox, and that competitive edge is expected stateside.

Speaker 1:

This isn't just a new product. It's a potential market disruptor that could democratize access to neurotoxic treatments while squeezing med spa profit margins. So what's the science behind Latiba? Let's geek out for a moment Latiba's technical name, and you're going to love this. Let's geek out for a moment Latibo's technical name, and you're going to love this Letibotulinumtoxin A-WLBG hints at its unique purification process. Unlike Botox, which uses human serum albumin, hugel's formula is albumin-free, so this reduces allergy risks. A 2024 study in dermatologic surgery showed comparable efficacy to Botox at 20 units for glabella lines with similar adverse event rates. Practically speaking, it's interchangeable with existing toxins such as Xeomin, botox and Zyphro. It's interchangeable with existing toxins such as Botox, xeomin or Dysport, but it arrives with a fresh economic playbook.

Speaker 1:

Now here's where it gets interesting. Hugo isn't just some startup. They're a titan in Asia's aesthetic space. Partnering with Benev gives them instant US scale. Benev's network includes 12,000 med spas and their real self-integration means patients researching quote affordable Botox unquote might stumble onto Latibo reviews mid-scroll. It's a digital native launch strategy that older brands simply can't replicate.

Speaker 1:

So let's talk dollars. If clinics pay, say, $8 per unit instead of $12 for Botox, the math gets compelling. So this is the retail rate that clinics may charge. For example, if a patient needs about 80 units for mass reduction, 40 units on the right and 40 units on the left, as well as platysma bands or combination thereof, let me. So let's talk dollars If clinics at retail offer a little less for let's talk dollars.

Speaker 1:

For example, if clinics offer Latibo at $8 a unit instead of $12 a unit for existing Botox, the math gets pretty compelling. For example, if a patient needs 80 units for masseter reduction and platysma bands at Botox pricing, that's currently about $960. With Latibo that's $640. So that's a $320 savings. Clinics could pocket the difference, but I suspect most will eventually lower the price and will reinvest this into expanded services. Imagine offering combo deals like the glass skin facial, which is a Korean trend.

Speaker 1:

Combining microdose neurotoxin at over 50 to 100, very tiny injections with hyaluronic acid and peptides At lower cost toxins. This becomes feasible. Or consider off-label areas like the mentalis muscle for pebbly chin. Previously injecting 8 to 10 units there felt wasteful for providers. So with Latibo suddenly it's a viable add-on. But here's the rub Lower costs could erode med spa profits a lot.

Speaker 1:

Compared to Botox. It may decrease the 60% profit margins that are typically seen on Botox. If Latibo forces a 25% price cuts, margins would drop to 45%. Can clinics offset that with volume? Maybe, but there's also brand perception to consider. A 2024 survey found 62% of patients equate higher costs with better quality. So overcoming that bias requires education, which is where Bnev's real self-partnership really shines. Their quote does Latibo last as long as Botox? Unquote FAQ is already trending leveraging patient reviews to build trust.

Speaker 1:

And let's address the elephant in the room Should neurotoxins be considered luxury items? Latibo's affordability might democratize access, but critics argue it could trivialize these medical-grade treatments. It's the tension between accessibility and perceived value that's going to shape the industry for years. Looking ahead, hugo's pipeline includes a next-gen neurotoxin lasting six months. If that's real and if that hits the US, the disruption we're seeing now will look like a warm-up For providers.

Speaker 1:

Adaptability is key. Bundling Latibo with premium services like thread lifts or exosome therapy could preserve margins For patients. There are more choices, lower costs and innovative treatments like under-eye microdosing, glass skin facials and more. So where does this leave us? Latibo isn't just another Botox alternative. It's a harbinger of affordability-driven innovation. So, whether it's enabling glass skin facials or making jawline sculpting accessible to middle-income patients, the implications are profound. As we close, I'd leave you with this If neurotoxins become as routine as facials, does that dilute their medical significance or finally align aesthetics with preventive care? I'd love to know your thoughts. Dm me on Instagram at DrRoyKim. You can also follow me on X at DrRoyKim as well. So, as always, thanks for tuning in to the Beauty Standard with Dr Roy Kim. Until next time, stay curious, stay informed and remember beauty isn't just skin deep.